THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI): Relationship to Hemostatic Alteration in Patients with β-Thalassemia

REFERENCES

• Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36–43.
   PubMed Web of Science ®Google Scholar
• Paolino E, Monetti VC, Granieri E, Boldrini P. Acute cerebrovascular insults in homozygous beta-thalassemia: a case report. J Neurol. 1983;230:37–41.
   PubMedGoogle Scholar
• Wong V, Yu YL, Liang RH, . Cerebral thrombosis in β-thalassemia/hemoglobin E disease. Stroke. 1990;21: 812–816.
   PubMedGoogle Scholar
• Sonakul D, Pacharee P, Laohapand T, . Pulmonary artery obstruction in thalassemia. Southeast J Trop Med Public Health. 1980;11:516–523.
   PubMedGoogle Scholar
• Sonakul D, Fucharoen S. Brain pathology in 6 fatal cases of post transfusion hypertension, convulsion and cerebral hemorrhage syndrome. Southeast Asian J Trop Med Public Health. 1992;23(Suppl 2):116–119.
   PubMedGoogle Scholar
• Taher A, Abou-Mourad Y, Abchee A, . Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002;26:107–112.
   PubMed Web of Science ®Google Scholar
• Michaeli J, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Haematol. 1992;87:71–74.
   PubMed Web of Science ®Google Scholar
• Eldor A, Durst R, Hy-Am E, . A chronic hyper-coagulable state in patients with beta-thalassemia major is already present in childhood. Br J Haematol. 1999;107:739–746.
   PubMed Web of Science ®Google Scholar
• Angchaisuksiri P, Atichartakarn V, Aryurachai K, . Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease. Am J Hematol. 2007;82:1001–1004.
   PubMed Web of Science ®Google Scholar
• Visudhiphan S, Ketsa-Ard K, Tumliang S, Piankijagum A. Significance of blood coagulation and platelet profiles in relation to pulmonary thrombosis in beta-thalassemia/Hb E. Southeast Asian J Trop Med Public Health. 1994;25:449–456.
   PubMedGoogle Scholar
• Hussain MA, Hutton RA, Pavlidou O, Hoffbrand AV. Platelet function in beta-thalassemia major. J Clin Pathol. 1979;32:429–433.
   PubMedGoogle Scholar
• Lee KF. Fatal intra-cranial haemorrhage in 2 cases of beta-thalassemia major. Med J Malaysia. 1995;50:110–113.
   PubMedGoogle Scholar
• Naithani R, Chandra J, Narayan S, . Thalassemia major—on the verge of bleeding or thrombosis? Hematology. 2006;11:57–61.
   PubMed Web of Science ®Google Scholar
• Sharma S, Raina V, Chandra J, . Lupus anticoagulant and anticardiolipin antibodies in polytransfused beta-thalassemia major. Hematology. 2006;11:287–290.
   PubMed Web of Science ®Google Scholar
• Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun. 1989;162: 933–939.
   PubMedGoogle Scholar
• Eaton DL, Malloy BE, Tsai SP, . Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem. 1991;266:21833–21838.
   PubMed Web of Science ®Google Scholar
• Wang W, Hendriks DF, Scharpé SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem. 1994;269:15937–15944.
   PubMedGoogle Scholar
• Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477–14484.
   PubMed Web of Science ®Google Scholar
• Wang W, Beffa MB, Baizar L, . A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem. 1998;273:27167–27181.
   Google Scholar
• Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26:2445–2453.
   PubMedGoogle Scholar
• Mosnier LO, Von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of coagulation. Thromb Haemost. 1998;80:829–835.
   PubMed Web of Science ®Google Scholar
• Silveira A, Schatteman K, Goossens F, . Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364–368.
   PubMed Web of Science ®Google Scholar
• van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855–2859.
   PubMed Web of Science ®Google Scholar
• Franco R, Fagundes MG, Meijers JCM, . Identification of polymorphisms in the 5’-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica. 2001;86:510–517.
   PubMedGoogle Scholar
• Henry M, Aubert H, Morange PE, . Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that the plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053–2058.
   PubMedGoogle Scholar
• Tregouet DA, Aubert H, Henry M, . Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet. 2001;109:191–197.
   PubMedGoogle Scholar
• Mosnier LO, Buijtenhuijs P, Marx PF, . Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood. 2003;101:4844–4846.
   PubMed Web of Science ®Google Scholar
• Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability and enzymatic properties. J Biol Chem. 1998;273:2127–2135.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Wada H, Watanabe Y, . Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res. 2001;104:1–6.
   PubMedGoogle Scholar
• Sosothikul D, Seksarn P, Pongsewalak S, . Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost. 2007;97:627–634.
   Google Scholar
• Sonmez M, Aydin K, Durmus A, . Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever. J Infect. 2007;55:184–187.
   PubMed Web of Science ®Google Scholar
• Tripatara A, Jetsrisuparb A, Teeratakulpisarn J, Kuaha K. Hemostatic alterations in splenectomized and non splenectomized patients with beta-thalassemia/ hemoglobin E disease. Thromb Res. 2007;120:805–810.
   PubMed Web of Science ®Google Scholar
• Prati D, Maggioni M, Milani S, et al; Cooleycare Cooperative Group. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89:1179–1186.
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Green TC, . An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2:3.
   PubMedGoogle Scholar
• Telfer PT, Prestcott E, Holden S, . Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. Br J Haematol. 2000;110:971–977.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Butensky E, Fung E, . Comparison of organ dysfunction in transfused patients with SCD or beta-thalassemia. Am J Hematol. 2005;80:70–74.
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost. 2001;85:667–670.
   PubMedGoogle Scholar
• Gresele P, Binetti BM, Branca G, . TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res. 2008;121:763–768.
   PubMedGoogle Scholar
• el-Gohary A, Hassan A, Nooman Z, . High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop. 1995;59:155–161.
   PubMedGoogle Scholar
• el-Nanawy AA, el-Azzouni OF, Soliman AT, . Prevalence of hepatitis-C antibody seropositivity in healthy Egyptian children and four high risk groups. J Trop Pediatr. 1995;41:341–343.
   PubMedGoogle Scholar
• Heylen E, Miljic P, Willemse J, . Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res. 2009;124:427–432.
   PubMedGoogle Scholar
• Shebl SS, el Sharkawy HM, el Fadaly NH. Hemostatic disorders in non splenectomized and splenectomized thalassemic children. East Mediterr Health J. 1999;5:1171–1177.
   PubMedGoogle Scholar
• Nathan DG. Thalassemia: the continued challenge. Ann N Y Acad Sci. 2005;1054:1–10.
   PubMedGoogle Scholar
• Opartkiattikul N, Funahara Y, Hijikata-Okunomiya A, Yamaguchi N, Fucharoen S, Talalak P. Detection of PF3 availability in whole blood from volunteers and beta-thalassemia/HbE patients: a promising method for prediction of thrombotic tendency. Southeast Asian J Trop Med Public Health. 1992;23(Suppl 2):52–59.
   PubMedGoogle Scholar
• Panigrahi I, Agarwal S. Thromboembolic complications in beta-thalassemia: beyond the horizon. Thromb Res. 2007;120:783–789.
   PubMed Web of Science ®Google Scholar